Faron Pharmaceuticals Oy
LSE:FARN
Income Statement
Earnings Waterfall
Faron Pharmaceuticals Oy
Revenue
|
0
EUR
|
Operating Expenses
|
-28.6m
EUR
|
Operating Income
|
-28.6m
EUR
|
Other Expenses
|
-2.4m
EUR
|
Net Income
|
-30.9m
EUR
|
Income Statement
Faron Pharmaceuticals Oy
Dec-2015 | Jun-2016 | Dec-2016 | Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
1
N/A
|
0
-6%
|
1
+94%
|
1
-44%
|
0
N/A
|
0
N/A
|
0
-5%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Gross Profit | ||||||||||||||||||
Cost of Revenue |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Gross Profit |
0
N/A
|
1
+3%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
(6)
|
(7)
|
(11)
|
(14)
|
(21)
|
(28)
|
(20)
|
(26)
|
(13)
|
(14)
|
(17)
|
(20)
|
(21)
|
(24)
|
(27)
|
(27)
|
(29)
|
|
Selling, General & Administrative |
(3)
|
(3)
|
(2)
|
(3)
|
(3)
|
(4)
|
(4)
|
(5)
|
(3)
|
(4)
|
(5)
|
(5)
|
(10)
|
(11)
|
(7)
|
(8)
|
(9)
|
|
Research & Development |
(4)
|
(6)
|
(9)
|
(11)
|
(19)
|
(25)
|
(16)
|
(21)
|
(10)
|
(11)
|
(14)
|
(17)
|
(17)
|
(18)
|
(21)
|
(19)
|
(19)
|
|
Depreciation & Amortization |
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
|
Other Operating Expenses |
1
|
2
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
2
|
3
|
6
|
5
|
1
|
0
|
0
|
|
Operating Income |
(6)
N/A
|
(7)
-18%
|
(10)
-41%
|
(13)
-36%
|
(21)
-57%
|
(28)
-35%
|
(20)
+28%
|
(26)
-32%
|
(13)
+50%
|
(14)
-6%
|
(17)
-20%
|
(20)
-20%
|
(21)
-6%
|
(24)
-14%
|
(27)
-14%
|
(27)
+2%
|
(29)
-6%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(1)
|
(2)
|
(2)
|
|
Total Other Income |
(0)
|
(0)
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
|
Pre-Tax Income |
(6)
N/A
|
(7)
-21%
|
(10)
-35%
|
(14)
-34%
|
(21)
-56%
|
(28)
-33%
|
(20)
+28%
|
(26)
-32%
|
(13)
+50%
|
(14)
-7%
|
(17)
-19%
|
(20)
-19%
|
(21)
-5%
|
(24)
-12%
|
(29)
-21%
|
(29)
-2%
|
(31)
-5%
|
|
Net Income | ||||||||||||||||||
Tax Provision |
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(6)
|
(7)
|
(10)
|
(14)
|
(21)
|
(28)
|
(20)
|
(26)
|
(13)
|
(14)
|
(17)
|
(20)
|
(21)
|
(24)
|
(29)
|
(29)
|
(31)
|
|
Net Income (Common) |
(6)
N/A
|
(7)
-20%
|
(10)
-36%
|
(14)
-34%
|
(21)
-55%
|
(28)
-33%
|
(20)
+28%
|
(26)
-32%
|
(13)
+50%
|
(14)
-7%
|
(17)
-19%
|
(20)
-19%
|
(21)
-5%
|
(24)
-12%
|
(29)
-21%
|
(29)
-2%
|
(31)
-5%
|
|
EPS (Diluted) |
-0.3
N/A
|
-0.32
-7%
|
-0.42
-31%
|
-0.49
-17%
|
-0.76
-55%
|
-0.89
-17%
|
-0.65
+27%
|
-0.7
-8%
|
-0.37
+47%
|
-0.31
+16%
|
-0.37
-19%
|
-0.42
-14%
|
-0.42
N/A
|
-0.45
-7%
|
-0.52
-16%
|
-0.46
+12%
|
-0.48
-4%
|